Fujifilm Diosynth Biotechnologies breaks ground on new innovation centre in Texas
August 21, 2020 – Fujifilm Diosynth Biotechnologies, a manufacturing company for biologics, has held a virtual ground-breaking ceremony, signaling the beginning of construction work on its Advanced Therapies Innovation Center in the city of College Station, Texas.
Being built with an investment of $55m, the 60,000ft² building will include process development and innovation laboratories to support advanced therapy projects.
The building will sit on the 22-care land parcel that the company acquired from Lake Walk this June. The new laboratories are expected to have BSL-2 capabilities with upstream, downstream and analytical development technologies.
It is also expected to triple the company’s advanced therapies process development capabilities at the site. When operational, the innovation centre will create up to 100 jobs in College Station area.
Fujifilm Diosynth Biotechnologies, Texas chief operating officer Gerry Farrell said: “We remain committed to provide leading, future proofed end-to-end gene therapy solutions, from pre-clinical to commercial launch.
“This is aligned with core purpose to be a Partner for Life as we support our customers in the advancement of tomorrow’s medicines.”
The virtual groundbreaking ceremony was attended by the company’s officials, government representatives, officials and others including College Station Mayor Karl Mooney, County Judge Duane Peters, City of Bryan Mayor Andrew Nelson, William Cole Companies developer Spencer Clements and Brazos Valley Economic Development Corporation chair of the board Mike Gentry.
Last month, the company announced that its College Station site will supportCovid-19 vaccine candidate manufacturing, as part of the US Government’s programme Operation Warp Speed, which aims to start delivering millions of doses of effective vaccine for Covid-19 to people in the US.
The Biomedical Advanced Research and Development Authority (BARDA) at the US Department of Health and Human Services had issued the order to the company for the manufacture of the vaccine through the end of 2021.